

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



CAY10487

Item No. 10006480

CAS Registry No.: 778624-05-8

Formal Name: N-[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-

2-propenyl]-L-alanine, methyl ester

Synonym: 3,4-Dihydrocinnamic Acid (L-alanine

methyl ester) amide


λ_{max}: 220, 242, 297, 325 nm UV/Vis.:

MF. C₁₃H₁₅NO₅ 265.3 FW: **Purity:** ≥98%

Supplied as: A crystalline solid

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Labratory Procedures

CAY10487 is supplied as a crystalline solid. A stock solution may be made by dissolving the CAY10487 in an organic solvent purged with an inert gas. CAY10487 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of CAY10487 in these solvents is at least 30 mg/ml.

CAY10487 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CAY10487 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. CAY10487 has a solubility of 0.35 mg/ml in a 1:5 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

The early stage of atherosclerosis is characterized by the aggregation of foam cells, so called a fatty streak, in the inner arterial wall. CAY10487 inhibits formation of fatty streak lesions of the thoracic aorta in high cholesterol-fed rabbits without affecting plasma lipid profiles or significantly inhibiting ACAT-1 or ACAT-2 activity. 1,2 The percent area occupied by the atherosclerotic lesion in rabbits supplemented with 0.05% CAY10487 in the diet was 16.1% compared to 53.5% in control rabbits. CAY10487 also exhibits antioxidant activity, inhibiting copper-mediated oxidation of low-density lipoprotein by about 75% at a concentration of $2 \mu M.^2$

References

- 1. Lee, S., Lee, C.-H., Oh, J.-H., et al. Anti-atherogenic effects of 3,4-dihydroxy hydrocinnamides. Bioorg. Medicinal Chem. Letters 13, 2681-2682 (2003).
- 2. Lee, S., Han, J.-M., Kim, H., et al. Synthesis of cinnamic acid derivatives and their inhibitory effects on LDL-oxidation, acyl-CoA: Cholesterol acyltransferase-1 and -2 activity, and decrease of HDL-particle size. Bioorg. Medicinal Chem. Letters 14, 4677-4681 (2004).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website

Copyright Cayman Chemical Company, 11/10/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM